A · Agilent Technologies, Inc.
$153.84
-3.85 (-2.44%)
At close · Aug 28
Market Cap
$43.45B
Shares
282.43M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$6.95B
+6.7%
FY2025
Net Income
$1.3B
+1.1%
FY2025
Gross Margin
52.43%
-1.9pp
FY2025
Operating Margin
21.29%
-1.6pp
FY2025
Diluted EPS
$4.57
+3.2%
FY2025
Operating Cash Flow
$1.56B
-11%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.49B – $7.51B | $7.23B | $6.95BG | $6.51BG | $6.83BG | $6.85BG | $6.32B | $5.34B | $5.16B | $4.91B | $4.47B | $4.2B | $4.04B | $4.05B | $3.89B | $6.86B | $6.62B | $5.44B | $4.48B | $5.77B | $5.42B | |
| — | $3.42B | $3.31B | $2.98B | $3.37B | $3.13B | $2.91B | $2.5B | $2.36B | $2.23B | $2.06B | $2.01B | $2B | $2.07B | $1.99B | $3.25B | $3.09B | $2.51B | $2.19B | $2.58B | $2.45B | |
| — | $3.81B | $3.64B | $3.54B | $3.47B | $3.72B | $3.41B | $2.84B | $2.81B | $2.68B | $2.41B | $2.2B | $2.04B | $1.98B | $1.91B | $3.6B | $3.53B | $2.93B | $2.29B | $3.2B | $2.97B | |
| — | — | 52.43% | 54.3% | 50.71% | 54.35% | 53.92% | 53.14% | 54.33% | 54.54% | 53.87% | 52.28% | 50.54% | 48.81% | 48.97% | 52.55% | 53.35% | 53.82% | 51.15% | 55.35% | 54.78% | |
| — | $473M | $455M | $479M | $481M | $467M | $441M | $495M | $404M | $387M | $341M | $329M | $330M | $358M | $337M | $668M | $649M | $612M | $642M | $704M | $685M | |
| — | $1.79B | $1.71B | $1.57B | $1.63B | $1.64B | $1.62B | $1.5B | $1.46B | $1.39B | $1.25B | $1.25B | $1.19B | $1.2B | $1.18B | $1.82B | $1.81B | $1.75B | $1.6B | $1.7B | $1.7B | |
| — | $88M | $105M | $105M | $140M | $192M | $195M | $186M | $128M | $110M | $120M | $154M | $158M | $189M | $190M | $136M | $111M | $76M | $45M | $53M | — | |
| — | $277M | $288M | $257M | $271M | $317M | $321M | $308M | $238M | $210M | $212M | $246M | $253M | $384M | $372M | $301M | $253M | $202M | $162M | $201M | $191M | |
| — | $53M | $82M | $76M | $46M | — | — | — | — | — | — | — | $6M | $68M | $53M | $0 | $2M | $64M | $252M | $0 | — | |
| — | $5.68B | $5.47B | $5.02B | $5.48B | $5.23B | $4.97B | $4.49B | $4.22B | $4.01B | $3.67B | $3.59B | $3.52B | $3.63B | $3.51B | $5.74B | $5.54B | $4.88B | $4.43B | $4.98B | — | |
| — | $1.56B | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B | $846M | $941M | $904M | $807M | $615M | $522M | $419M | $386M | $1.12B | $1.07B | $566M | $47M | $795M | $584M | |
| — | — | 21.29% | 22.86% | 19.76% | 23.63% | 21.32% | 15.85% | 18.23% | 18.4% | 18.05% | 14.64% | 12.93% | 10.35% | 9.91% | 16.32% | 16.19% | 10.4% | 1.05% | 13.77% | 10.77% | |
| — | $1.83B | $1.77B | $1.75B | $1.62B | $1.94B | $1.67B | $1.15B | $1.18B | $1.11B | $1.02B | $861M | $775M | $803M | $758M | $1.42B | $1.32B | $768M | $209M | $996M | $775M | |
| — | $105M | $112M | $96M | $95M | $84M | $81M | $78M | $74M | $75M | $79M | $72M | $66M | $110M | $107M | $101M | $86M | $96M | $88M | $123M | — | |
| — | $61M | $62M | $80M | $51M | $9M | $2M | $8M | $36M | $38M | $22M | $11M | $7M | $9M | $7M | $9M | $14M | $20M | $29M | $113M | $172M | |
| — | $69M | $6M | $49M | $33M | -$39M | $92M | $66M | $16M | $79M | $53M | -$10M | $17M | -$89M | $7M | $16M | $33M | $70M | $19M | $30M | $5M | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | -$10M | -$9M | -$7M | -$2M | — | — | — | — | — | — | |
| — | $1.58B | $1.44B | $1.52B | $1.34B | $1.5B | $1.36B | $842M | $919M | $946M | $974M | $859M | $767M | $763M | $732M | $1.38B | $1.31B | $938M | $7M | $815M | $670M | |
| — | $166M | $132M | $232M | $99M | $250M | $150M | $123M | -$152M | $630M | $119M | $82M | $42M | -$3M | $68M | -$110M | $20M | $8M | $38M | $122M | $32M | |
| — | $1.41B | $1.3B | $1.29B | $1.24B | $1.25B | $1.21B | $719M | $1.07B | $316M | $684M | $462M | $401M | $549M | $734M | $1.15B | $1.01B | $684M | -$31M | $693M | $638M | |
| — | — | 18.75% | 19.8% | 18.15% | 18.31% | 19.15% | 13.47% | 20.74% | 6.43% | 15.3% | 10.99% | 9.93% | 13.56% | 18.85% | 16.81% | 15.3% | 12.56% | -0.69% | 12% | 11.77% | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $7M | $3M | — | |
| — | — | $1.38B | $1.31B | $1.26B | $1.19B | $1.45B | $711M | $972M | $254M | $841M | $350M | $12M | $124M | $936M | $926M | $1.22B | $781M | -$38M | $107M | $890M | |
| USD/shares | — | $5.00 | $4.59 | $4.44 | $4.22 | $4.19 | $3.98 | $2.33 | $3.41 | $0.98 | $2.12 | $1.42 | $1.20 | $1.65 | $2.15 | $3.31 | $2.92 | $1.97 | -$0.09 | $1.91 | $1.62 |
| USD/shares | $6.18 – $6.21* | $4.98 | $4.57G | $4.43G | $4.19G | $4.18G | $3.94 | $2.30 | $3.37 | $0.97 | $2.10 | $1.40 | $1.20 | $1.62 | $2.13 | $3.27 | $2.85 | $1.94 | -$0.09 | $1.87 | $1.57 |
| shares | — | — | 284M | 290M | 294M | 299M | 304M | 309M | 314M | 321M | 322M | 326M | 333M | 333M | 341M | 348M | 347M | 347M | 346M | 363M | 394 |
| shares | — | — | 285M | 291M | 296M | 300M | 307M | 312M | 318M | 325M | 326M | 329M | 335M | 338M | 345M | 353M | 355M | 353M | 346M | 371M | 406 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $11.87B in buybacks, $2.82B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.22×
Peer median 7.11×
EV/EBIT
28.94×
Peer median 33.88×
P/E (TTM)
30.89×
Peer median 34.90×
Peer medians compare against the 20 similar-size Diagnostics & Research companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $2,908,000,000 | $2,747,000,000 | $2,656,000,000 | $1,452,000,000 | $1,360,000,000 | $1,177,000,000 | $1,840,000,000 | $1,701,000,000 |
| Life Sciences and Diagnostics Markets | $2,726,000,000 | $2,466,000,000 | $2,780,000,000 | — | — | — | — | — |
| Applied Markets | $1,314,000,000 | $1,297,000,000 | $1,397,000,000 | — | — | — | — | — |
| Diagnostics and Genomics | — | $1,651,000,000 | $1,755,000,000 | $1,766,000,000 | $1,296,000,000 | $1,047,000,000 | $1,021,000,000 | $943,000,000 |
| Life Sciences and Applied Markets | — | $3,215,000,000 | $3,510,000,000 | $3,630,000,000 | $3,663,000,000 | $3,115,000,000 | $2,302,000,000 | $2,270,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Rest of World | $3,382,000,000 | $3,047,000,000 | $3,040,000,000 | $2,964,000,000 | $2,887,000,000 | $2,500,000,000 | $2,525,000,000 | $2,485,000,000 |
| United States | $2,342,000,000 | $2,246,000,000 | $2,410,000,000 | $2,385,000,000 | $2,159,000,000 | $1,752,000,000 | $1,619,000,000 | $1,414,000,000 |
| China | $1,224,000,000 | $1,217,000,000 | $1,383,000,000 | $1,499,000,000 | $1,273,000,000 | $1,087,000,000 | $1,019,000,000 | $1,015,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Non Instrumentationand Other | $4,521,000,000 | $4,156,000,000 | $4,091,000,000 | $3,941,000,000 | $3,662,000,000 | $3,090,000,000 | $3,013,000,000 | — |
| Instrumentation | $2,427,000,000 | $2,354,000,000 | $2,742,000,000 | $2,907,000,000 | $2,657,000,000 | $2,249,000,000 | $2,150,000,000 | — |
| Product | — | — | — | — | — | — | — | $3,746,000,000 |
| Service Other | — | — | — | — | — | — | — | $1,168,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $946,000,000 | $925,000,000 | $839,000,000 | $370,000,000 | $323,000,000 | $272,000,000 | $475,000,000 | $388,000,000 |
| Life Sciences and Diagnostics Markets | $536,000,000 | $484,000,000 | $673,000,000 | — | — | — | — | — |
| Applied Markets | $301,000,000 | $312,000,000 | $363,000,000 | — | — | — | — | — |
| Diagnostics and Genomics | — | $320,000,000 | $363,000,000 | $390,000,000 | $273,000,000 | $192,000,000 | $185,000,000 | $173,000,000 |
| Life Sciences and Applied Markets | — | $877,000,000 | $1,049,000,000 | $1,097,000,000 | $1,017,000,000 | $792,000,000 | $542,000,000 | $543,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | 32.5% | 33.7% | 31.6% | 25.5% | 23.8% | 23.1% | 25.8% | 22.8% |
| Life Sciences and Diagnostics Markets | 19.7% | 19.6% | 24.2% | — | — | — | — | — |
| Applied Markets | 22.9% | 24.1% | 26% | — | — | — | — | — |
| Diagnostics and Genomics | — | 19.4% | 20.7% | 22.1% | 21.1% | 18.3% | 18.1% | 18.3% |
| Life Sciences and Applied Markets | — | 27.3% | 29.9% | 30.2% | 27.8% | 25.4% | 23.5% | 23.9% |
Key facts
CIK
1090872
CUSIP
00846U101
13F (30d)
802 filings
756 filers
Visit website
Investor relations